174 related articles for article (PubMed ID: 24682466)
1. 19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.
Chang CH; Drechsel DA; Kitson RR; Siegel D; You Q; Backos DS; Ju C; Moody CJ; Ross D
Mol Pharmacol; 2014 Jun; 85(6):849-57. PubMed ID: 24682466
[TBL] [Abstract][Full Text] [Related]
2. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Mol Pharmacol; 2006 Oct; 70(4):1194-203. PubMed ID: 16825487
[TBL] [Abstract][Full Text] [Related]
3. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.
Guo W; Reigan P; Siegel D; Ross D
Drug Metab Dispos; 2008 Oct; 36(10):2050-7. PubMed ID: 18635747
[TBL] [Abstract][Full Text] [Related]
4. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
6. A Novel Hsp90 Inhibitor Activates Compensatory Heat Shock Protein Responses and Autophagy and Alleviates Mutant A53T α-Synuclein Toxicity.
Xiong R; Zhou W; Siegel D; Kitson RR; Freed CR; Moody CJ; Ross D
Mol Pharmacol; 2015 Dec; 88(6):1045-54. PubMed ID: 26405178
[TBL] [Abstract][Full Text] [Related]
7. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
[TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs.
Samuni Y; Ishii H; Hyodo F; Samuni U; Krishna MC; Goldstein S; Mitchell JB
Free Radic Biol Med; 2010 Jun; 48(11):1559-63. PubMed ID: 20211249
[TBL] [Abstract][Full Text] [Related]
9. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins.
Reigan P; Siegel D; Guo W; Ross D
Mol Pharmacol; 2011 May; 79(5):823-32. PubMed ID: 21285336
[TBL] [Abstract][Full Text] [Related]
10. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
11. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
Siegel D; Shieh B; Yan C; Kepa JK; Ross D
J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
[TBL] [Abstract][Full Text] [Related]
12. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
13. Redox properties and thiol reactivity of geldanamycin and its analogues in aqueous solutions.
Samuni A; Goldstein S
J Phys Chem B; 2012 Jun; 116(22):6404-10. PubMed ID: 22591491
[TBL] [Abstract][Full Text] [Related]
14. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications.
Cysyk RL; Parker RJ; Barchi JJ; Steeg PS; Hartman NR; Strong JM
Chem Res Toxicol; 2006 Mar; 19(3):376-81. PubMed ID: 16544941
[TBL] [Abstract][Full Text] [Related]
15. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma.
Breinig M; Caldas-Lopes E; Goeppert B; Malz M; Rieker R; Bergmann F; Schirmacher P; Mayer M; Chiosis G; Kern MA
Hepatology; 2009 Jul; 50(1):102-12. PubMed ID: 19441108
[TBL] [Abstract][Full Text] [Related]
16. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
17. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Siegel D; Yan C; Ross D
Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
[TBL] [Abstract][Full Text] [Related]
18. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
Douglas M; Lim AR; Porter JR; West K; Pink MM; Ge J; Wylie AA; Tibbits TT; Biggs K; Curtis M; Palombella VJ; Adams J; Fritz CC; Normant E
Mol Cancer Ther; 2009 Dec; 8(12):3369-78. PubMed ID: 19952119
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
